In the RESPONSE trial
, patients treated with ruxolitinib showed better disease control, including controlled hematocrit levels without the need for phlebotomy, reduced spleen size and improved symptom management compared to current therapies.
To support continued development of NT100, including addition of Ph2 RESPONSE trial
in recurrent pregnancy loss indication
Greer, a leading developer and provider of allergy immunotherapy products, today announced the results of its Phase IIb double-blind placebo-controlled dose response trial
for the sublingual-oral immunotherapy (SLIT) administration of its standardized short ragweed pollen extract.
Greer, a leading developer and provider of allergy immunotherapy products, announced the initiation of a Phase IIB double-blind placebo controlled dose response trial
for sublingual-oral immunotherapy of its standardized short ragweed extract after receiving clearance of the study protocol from the FDA.